Advertisement
Screener

Lantern Pharma Inc. (LTRN) Amortization of Debt Issuance Costs

2.8 / 5 stars · 68/120 Roast Me

Lantern Pharma Inc. Amortization of Debt Issuance Costs

Lantern Pharma Inc. (LTRN) reported Amortization of Debt Issuance Costs of $512.00 thousand for the 1-month period ending 2026-05-31, per its 10-Q filed 2026-08-14.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:AmortizationOfFinancingCosts · last filed 2026-08-14

  • Lantern Pharma Inc. amortization of debt issuance costs for the quarter ending 2025-12-31 was $30.60K.
  • Lantern Pharma Inc. amortization of debt issuance costs for fiscal 2025 was $61.32K.
Period endAmortization of Debt Issuance Costs 1 monthAmortization of Debt Issuance Costs 3 monthAmortization of Debt Issuance Costs 9 monthAmortization of Debt Issuance Costs 12 month
2026-05-31$512.00K
10-Q · filed 2026-08-14
2025-12-31$30.60K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30
$61.32K
10-K · filed 2026-03-30
2025-09-30$30.72K
10-Q · filed 2025-11-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
Citius Pharmaceuticals, Inc. (CTXR)United States$0.016B-133.06
Anebulo Pharmaceuticals, Inc. (ANEB)United States$0.015B
Korsana Biosciences, Inc. (CYCN)United States$0.016B
ACTUATE THERAPEUTICS, INC. (ACTU)United States$0.015B
Tvardi Therapeutics, Inc. (TVRD)United States$0.014B
Vyome Holdings, Inc (HIND)United States$0.014B-1.38
BullFrog AI Holdings, Inc. (BFRG)United States$0.014B
Pasithea Therapeutics Corp. (KTTA)United States$0.017B-0.81
Allarity Therapeutics, Inc. (ALLR)United States$0.017B-1.66
LISATA THERAPEUTICS, INC. (LSTA)United States$0.014B-2.13